Outcome of interval debulking in advanced ovarian Cancer patients

Asian Pacific Journal of Cancer Prevention

Volumn 9, Issue 3, 2008, Pages 519-524

  Suprasert, Prapaporn ^a   Tiyanon, Jittima ^a   Kietpeerakool, Chumnarn ^a  

^a Faculty of Medicine Chiang Mai University   (Thailand)

Author keywords

Advanced epithelial ovarian cancer; Interval debulking; Neoadjuvant chemotherapy

Indexed keywords

EID: 67650899063     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Bertelsen K (1990). Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study. Gynecol Oncol, 38, 203-9.
2. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002). Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol, 20, 1248-59.
3. Baekelandt M (2003). The potential role of neoadjuvant chemotherapy in advanced ovarian cancer. Int J Gynecol Cancer, 13, 163-8.
4. Bristow RE, Chi DS (2006). Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol, 103, 1070-6.
5. Bristow RE, Eisenhauer EL, Santillan A, Chi DS (2007). Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol Oncol, 104, 480-90.
6. Chi DS, Liao JB, Leon LF, et al (2001). Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol, 82, 532-7.
7. Delgado G, Oram DH, Petrilli ES (1984). Stage III epithelial ovarian cancer: the role of maximal surgical reduction. Gynecol Oncol, 18, 293-8.
8. Griffiths CT (1975). Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr, 42, 101-4.
9. Gallo A, Frigerio L (2003). Neoadjuvant chemotherapy and surgical considerations in ovarian cancer. Curr Opin Obstet Gynecol, 15, 25-31.
10. Hacker NF, Berek JS, Lagasse LD, Nieberg RK, Elashoff RM (1983). Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol, 61, 413-20.
11. Hoskins WJ, McGuire WP, Brady MF, et al (1994). The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol, 170, 974-9.
12. Huober J, Meyer A, Wagner U, Wallwiener D (2002). The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancer. J Cancer Res Clin Oncol, 128, 153-60.
13. Inciura A, Simavicius A, Juozaityte E, et al (2006). Comparison of adjuvant and neoadjuvant chemotherapy in the management of advanced ovarian cancer: a retrospective study of 574 patients. BMC Cancer, 6, 153.
14. Jacob JH, Gershenson DM, Morris M, et al (1991). Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. Gynecol Oncol, 42, 146-50.
15. Kuhn W, Rutke S, Späthe K, et al (2001). Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer, 92, 2585-91.
16. Lawton FG, Redman CW, Luesley DM, Chan KK, Blackledge G (1989). Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer. Obstet Gynecol, 73, 61-5.
17. Lawton F, Luesley D, Redman C, et al (1990). Feasibility and outcome of complete secondary tumor resection for patients with advanced ovarian cancer. J Surg Oncol, 45, 14-9.
18. Lee SJ, Kim BG, Lee JW, et al (2006). Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery. J Obstet Gynaecol Res, 32, 99-106.
19. Morice P, Dubernard G, Rey A, et al (2003). Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer. J Am Coll Surg, 197, 955-63.
20. Neijt JP, ten Bokkel Huinink WW, van der Burg ME, et al (1987). Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. J Clin Oncol, 5, 157-68.
21. Pecorelli S, Odicino F, Favalli G (2002). Interval debulking surgery in advanced epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol, 16, 573-83.
22. Redman CW, Blackledge G, Lawton FG, et al (1990). Early second surgery in ovarian cancer--improving the potential for cure or another unnecessary operation? Eur J Surg Oncol, 16, 426-9.
23. Redman CW, Warwick J, Luesley DM, et al (1994). Intervention debulking surgery in advanced epithelial ovarian cancer. Br J Obstet Gynaecol, 101, 142-6.
24. Rose PG, Nerenstone S, Brady MF, et al (2004). Gynecologic Oncology Group. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med, 351, 2489-97.
25. Rafii A, Deval B, Geay JF, et al (2007). Treatment of FIGO stage IV ovarian carcinoma: results of primary surgery or interval surgery after neoadjuvant chemotherapy: a retrospective study. Int J Gynecol Cancer, 17, 777-83.
26. van der Burg ME, van Lent M, Buyse M, et al (1995). The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med, 332, 629-34.
27. Wils J, Blijham G, Naus A, et al (1986). Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide in stage III-IV epithelial ovarian carcinoma. J Clin Oncol, 4, 1068-73.